Homozygosity for Factor V Leiden Leads to Enhanced Thrombosis and Atherosclerosis in Mice
- 12 April 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American College of Cardiology
- Vol. 111 (14), 1822-1825
- https://doi.org/10.1161/01.cir.0000160854.75779.e8
Abstract
Background— Activated protein C resistance due to factor V Leiden (FVL) is a common genetic risk factor for venous thrombosis in humans. Although the impact of FVL on the development of venous thrombosis is well established, its effect on arterial thrombosis and atherosclerosis is controversial. Methods and Results— To determine the effect of the FVL mutation on arterial thrombosis in the mouse, wild-type ( Fv +/+ ), heterozygous FVL ( Fv Q /+ ), and homozygous FVL ( Fv Q/Q ) mice underwent photochemical carotid arterial injury to induce occlusive thrombosis. Fv Q/Q mice formed occlusive thromboses 27±3 minutes (n=7) after the onset of injury, which was significantly shorter than that observed for Fv +/+ mice (56±7 minutes, n=9, P Fv Q /+ mice (41±7 minutes, n=5) were intermediate ( P =0.5, compared with Fv +/+ ). To determine the source of FVL relevant to the enhanced vascular thrombosis, bone marrow transplantation experiments were performed between Fv +/+ and Fv Q/Q mice. Fv Q/Q mice transplanted with Fv +/+ bone marrow formed occlusive thromboses at 35±5 minutes (n=7, P Fv +/+ mice), whereas Fv +/+ mice transplanted with Fv Q/Q bone marrow occluded at 59±7 minutes (n=6, P Fv Q/Q mice). To assess the effect of the FVL mutation on the development of atherosclerosis, Fv Q/Q mice were crossed with the atherosclerosis-prone apolipoprotein E (ApoE)–deficient strain ( ApoE −/− ) to generate Fv Q/Q ,ApoE −/− mice. By 52 weeks of age, Fv Q/Q ,ApoE −/− mice (n=8) had developed more aortic atherosclerosis (40±6% lesion area) compared with Fv +/+ ,ApoE −/− mice (15±3% lesion area; n=12, P Conclusions— In conclusion, homozygosity for the FVL mutation in mice leads to enhanced arterial thrombosis and atherosclerosis. The source of the FVL leading to accelerated thrombosis appears to be circulating, non–platelet-derived plasma FVL.This publication has 22 references indexed in Scilit:
- The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasisBlood, 2003
- Biosynthetic origin and functional significance of murine platelet factor VBlood, 2003
- Fabry Disease in Mice Is Associated With Age-Dependent Susceptibility to Vascular ThrombosisJournal of the American Society of Nephrology, 2003
- Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analysesBlood, 2002
- Vascular-Bed–Specific Hemostasis and Hypercoagulable StatesThe New England Journal of Medicine, 1999
- Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.JCI Insight, 1998
- Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosisThe Lancet, 1994
- Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor VThe Lancet, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this modelJournal of Pharmacological Methods, 1991